Novartis pharma boss expects pressure on cancer drug prices

Payers are likely to put pressure on drugmakers to lower the cost of cancer medicines, particularly when alternative treatments are available, the head of Novartis’ pharma division said on Tuesday. “I think there will be increased pressure on oncology prices,” David Epstein, head of Novartis’ pharmaceutical division told an analyst call after the company reported fourth-quarter results. Earlier this month it said cost savings on expensive cancer treatments could be achieved if the company were involved earlier in the decision-making process.
Go to Source